nach oben

Archives of Osteoporosis

Erschienen in:

01.12.2018 | Original Article

Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study

verfasst von: Chih-Chien Hung, Chen-Yu Wang, Shau-Huai Fu, Rong-Sen Yang, Fei-Yuan Hsiao

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Summary

This nationwide cohort study examined the potential disease-modifying effect of anti-osteoporosis medication on hip osteoarthritis. The results revealed that the usage of anti-osteoporosis medication is not associated with decreased risk in undergoing total hip arthroplasty in patient with hip osteoarthritis.

Purpose

This study aimed to assess the association between use of anti-osteoporosis medications (AOMs) and the risk of undergoing total hip arthroplasty (THA) in patients with hip osteoarthritis (OA).

Methods

Using the 2008–2013 National Health Insurance Research Database, we identified patients who were first diagnosed as having hip OA. All identified patients were followed until THA, death of any cause, or December 31, 2013, whichever occurred first. All AOM exposures were divided into three categories: bisphosphonates use, non-bisphosphonates use, and no use of AOMs and assessed in a time-varying manners. The primary outcome was THA. The secondary outcome was the differences in the longitudinal utilization of NSAIDs between AOM users and non-users. Time-dependent Cox proportional hazards models were used to investigate the effect of AOM use on the risk of THA.

Results

We identified 35,870 patients who were first diagnosed as having hip OA and had no history of AOM use between 2009 and 2012. Among them, 3162 and 1667 patients had their first prescription of bisphosphonates and other non-bisphosphonates AOMs during the follow-up period. Mean age of bisphosphonates users, non-bisphosphonates users, and non-users was 75.62, 76.84, and 67.39 years, respectively. Bisphosphonates or non-bisphosphonates users did not show significant change when compared to non-users in terms of risk of undergoing THA [adjusted hazard ratio (aHR) 0.972, 95% confidence interval (CI) 0.743–1.273; aHR 0.926, 95% CI 0.672–1.277].

Conclusion

Our results showed that the use of AOMs is not associated with decreased risk of THA in patients with hip OA.

Nur mit Berechtigung zugänglich

Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Brandi ML et al (2013) Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum 43(3):303–313. https://doi.org/10.1016/j.semarthrit.2013.07.003 CrossRefPubMed

Litwic A, Edwards M, Dennison E, Cooper C (2013) Epidemiology and burden of osteoarthritis. Br Med Bull 105:185–199. https://doi.org/10.1093/bmb/lds038 CrossRefPubMed

Salmon JH, Rat AC, Sellam J, Michel M, Eschard JP, Guillemin F, Jolly D, Fautrel B (2016) Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthr Cartil 24(29):1500–1508. https://doi.org/10.1016/j.joca.2016.03.012 CrossRef

Berenbaum F (2013) Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr Cartil 21(1):16–21. https://doi.org/10.1016/j.joca.2012.11.012 CrossRef

Scanzello CR, Goldring SR (2012) The role of synovitis in osteoarthritis pathogenesis. Bone 51(2):249–257. https://doi.org/10.1016/j.bone.2012.02.012 CrossRefPubMedPubMedCentral

Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16(04):494–502. https://doi.org/10.1136/ard.16.4.485 CrossRefPubMedPubMedCentral

Ahlbäck S (1968) Osteoarthrosis of the knee. A radiographic investigation. Acta Radiol Diagn (Stockh) Suppl 277:7–72

Geusens PP, van den Bergh JP (2016) Osteoporosis and osteoarthritis: shared mechanisms and epidemiology. Curr Opin Rheumatol 28(2):97–103. https://doi.org/10.1097/BOR.0000000000000256 CrossRefPubMed

Neuprez A, Neuprez AH, Kurth W, Gillet P, Bruyère O, Reginster JY (2018) Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the "need for surgery". Aging Clin Exp Res 30:315–321. https://doi.org/10.1007/s40520-017-0780-1 CrossRefPubMed

10.

Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, Berenbaum F, Dennison E, Devogelaer JP, Hochberg M, Kanis J, Laslop A, McAlindon T, Reiter S, Richette P, Rizzoli R, Reginster JY (2015) Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging 32:179–187. https://doi.org/10.1007/s40266-015-0243-3 CrossRefPubMedPubMedCentral

11.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16(2):137–162. https://doi.org/10.1016/j.joca.2007.12.013 CrossRef

12.

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18(4):476–499. https://doi.org/10.1016/j.joca.2010.01.013 CrossRef

13.

Fajardo M, Di Cesare PE (2005) Disease-modifying therapies for osteoarthritis: current status. Drugs Aging 22(2):141–161. https://doi.org/10.2165/00002512-200522020-00005 CrossRefPubMed

14.

Per Q, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, Karsdal MA (2008) The disease modifying osteoarthritis drug (DMOAD): is it in the horizon? Pharmacol Res 58(1):1–7. https://doi.org/10.1016/j.phrs.2008.06.001 CrossRef

15.

Hunter DJ (2011) Pharmacologic therapy for osteoarthritis—the era of disease modification. Nat Rev Rheumatol 7(1):13–22. https://doi.org/10.1038/nrrheum.2010.178 CrossRefPubMed

16.

Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris TB, Wang BW, Kritchevsky SB (2004) Health, aging and body composition study. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis Arthritis Rheum 50(11):3516–3525. https://doi.org/10.1002/art.20627 CrossRefPubMed

17.

Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54(11):3494–3507. https://doi.org/10.1002/art.22160 CrossRefPubMed

18.

Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham CO 3rd (2008) Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the knee osteoarthritis structural arthritis randomized clinical trial. Osteoarthr Cartil 16(6):660–666. https://doi.org/10.1016/j.joca.2007.10.002 CrossRef

19.

Hwang JS, Chan DC, Chen JF, Cheng TT, Wu CH, Soong YK, Tsai KS, Yang RS (2014) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab 32(1):10–16. https://doi.org/10.1007/s00774-013-0495-0 CrossRefPubMed

20.

Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE (2013) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 24(2):511–521. https://doi.org/10.1007/s00198-012-1984-z CrossRefPubMed

21.

Fu SH, Wang CY, Yang RS, Wu FL, Hsiao FY (2017) Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan. J Bone Joint Surg Am 99(11):938–946. https://doi.org/10.2106/JBJS.16.00385 CrossRefPubMed

22.

Olivier E, Bruyère O, Richy F, Dardennes C, Reginster JY (2004) Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. J Bone Joint Surg Am 86-A(5):963–974

23.

Jenkins PJ, Clement ND, Hamilton DF, Gaston P, Patton JT, Howie CR (2013) Predicting the cost-effectiveness of total hip and knee replacement. Bone Joint J 95-B(1):115–121. https://doi.org/10.1302/0301-620X.95B1.29835 CrossRefPubMed

24.

Karlson EW, Mandl LA, Aweh GN, Sangha O, Liang MH, Grodstein F (2003) Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors. Am J Med 114(2):93–98. https://doi.org/10.1016/S0002-9343(02)01447-X CrossRefPubMed

25.

Flugsrud GB, Nordsletten L, Espehaug B, Havelin LI, Meyer HE (2002) Risk factors for total hip replacement due to primary osteoarthritis: a cohort study in 50,034 persons. Arthritis Rheum 46(3):675–682. https://doi.org/10.1002/art.10115 CrossRefPubMed

26.

Hsiao FY, Yang YC, Huang YT, Huang WF (2007) Using Taiwan’s National Health Insurance Research Databases for pharmacoepidemiology research. J Food Drug Anal 15:99–108

27.

Chen YC, Yeh HY, Wu JC, Haschler I, Chen TJ, Wetter T (2011) Taiwan’s National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics 86:365–380. https://doi.org/10.1007/s11192-010-0289-2 CrossRef

28.

Hsing AW, Ioannidis JP (2015) Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med 175(9):1527–1529. https://doi.org/10.1001/jamainternmed.2015.3540 CrossRefPubMed

29.

Zhou Z, Rahme E, Abrahamowicz M, Pilote L (2005) Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 162(10):1016–1023. https://doi.org/10.1093/aje/kwi307 CrossRefPubMed

30.

Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087. https://doi.org/10.1136/bmj.b5087 CrossRefPubMed

31.

Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399–424. https://doi.org/10.1080/00273171.2011.568786 CrossRefPubMedPubMedCentral

32.

Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15(12):1003–1008. https://doi.org/10.1007/s00198-004-1652-z CrossRefPubMed

33.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18(8):1023–1031. https://doi.org/10.1007/s00198-006-0322-8 CrossRefPubMed

34.

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401–2411. https://doi.org/10.1007/s00198-015-3253-4 CrossRefPubMedPubMedCentral

35.

Cremers SC, Pillai GC, Papapoulos SE (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates. Clin Pharmacokinet 44(6):551–570. https://doi.org/10.2165/00003088-200544060-00001 CrossRefPubMed

36.

Beaudart, C., Biver, E., Bruyère, O., Cooper, C., Al-Daghri, N., Reginster, J. Y., & Rizzoli, R. (2017). Quality of life assessment in musculo-skeletal health. Aging clinical and experimental research, 1–6. doi:https://doi.org/10.1007/s40520-017-0794-8 CrossRefPubMedPubMedCentral

37.

Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20(10):1633–1650. https://doi.org/10.1007/s00198-009-0920-3 CrossRefPubMed

38.

Hallberg I, Rosenqvist AM, Kartous L, Löfman O, Wahlström O, Toss G (2004) Health-related quality of life after osteoporotic fractures. Osteoporos Int 15(10):834–841. https://doi.org/10.1007/s00198-004-1622-5 CrossRefPubMed

39.

Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, Seeman E (2011) Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 22(11):2789–2798. https://doi.org/10.1007/s00198-011-1632-z CrossRefPubMedPubMedCentral

40.

Lin TC, Yang CY, Yang YH, Lin SJ (2013) Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women. J Clin Endocrinol Metab 98(12):4717–4726. https://doi.org/10.1210/jc.2013-1877 CrossRefPubMed

41.

Shabestari M, Vik J, Reseland JE, Eriksen EF (2016) Bone marrow lesions in hip osteoarthritis are characterized by increased bone turnover and enhanced angiogenesis. Osteoarthr Cartil 24(10):1745–1752. https://doi.org/10.1016/j.joca.2016.05.009 CrossRef

42.

Ahedi H, Aitken D, Blizzard L, Cicuttini F, Jones G (2014) A population-based study of the association between hip bone marrow lesions, high cartilage signal, and hip and knee pain. Clin Rheumatol 33(3):369–376. https://doi.org/10.1007/s10067-013-2394-0 CrossRefPubMed

43.

Taljanovic MS, Graham AR, Benjamin JB, Gmitro AF, Krupinski EA, Schwartz SA, Hunter TB, Resnick DL (2008) Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings and histopathology. Skelet Radiol 37(5):423–431. https://doi.org/10.1007/s00256-008-0446-3 CrossRef

44.

Nishii T, Tamura S, Shiomi T, Yoshikawa H, Sugano N (2013) Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. Clin Rheumatol 32(12):1759–1766. https://doi.org/10.1007/s10067-013-2338-8 CrossRefPubMed

45.

Reginster JY, Reiter-Niesert S, Bruyère O, Berenbaum F, Brandi ML, Branco J, Devogelaer JP, Herrero-Beaumont G, Kanis J, Maggi S, Maheu E, Richette P, Rizzoli R, Cooper C (2015) Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthr Cartil 23(12):2086–2093. https://doi.org/10.1016/j.joca.2015.07.001 CrossRef

46.

Lai YS, Wei HW, Cheng CK (2008) Incidence of hip replacement among national health insurance enrollees in Taiwan. J Orthop Surg Res 3(1):42. https://doi.org/10.1186/1749-799X-3 CrossRefPubMedPubMedCentral

Titel: Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study
verfasst von: Chih-Chien Hung
Chen-Yu Wang
Shau-Huai Fu
Rong-Sen Yang
Fei-Yuan Hsiao
Publikationsdatum: 01.12.2018
Verlag: Springer London
Erschienen in: Archives of Osteoporosis / Ausgabe 1/2018
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-018-0522-9

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Summary

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

New FRAX-based intervention and assessment thresholds for the Ecuadorian population

Judicious use of DXA-BMD in assessing fracture risk by using clinical risk factors in the Indian population

Prevention of low bone mass to achieve high bone density in Mexico: position of the Mexican Association for Bone and Mineral Metabolism

Association between alcohol consumption and bone mineral density in elderly Korean men and women

High prevalence of vitamin D deficiency and influencing factors among urban and rural residents in Tianjin, China